---
title: Illumina, Inc. (ILMN)
layout: default
nav_order: 541
---

# Illumina, Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 2/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $36.4 B

Illumina is a leading developer and manufacturer of life science tools and integrated systems for large-scale analysis of genetic variation and biological function.  Their products and services serve customers in a wide range of markets, including genomic sequencing and microarray-based solutions.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ILMN+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ILMN/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat:**

Illumina's moat derives primarily from **switching costs** and **network effects**, though both are weakening.  Switching costs are significant for existing customers due to the integration of Illumina's systems into their workflows, the extensive training required to operate them, and the substantial cost of replacing the equipment. Network effects exist as the value of Illumina's platform increases with the number of users, encouraging data sharing and collaboration within the user community.

> However, recent competitive pressures and the commoditization of some of its offerings are placing downward pressure on its moat.

**Justification for Moat Rating (3/5):**

* **Switching Costs (Positive):**  Illumina's instruments are expensive and require specialized training, creating lock-in.  Data generated on Illumina platforms is often difficult to transfer to competing systems. This dynamic is similar to the one highlighted in "The Little Book That Builds Wealth" where companies like Intuit benefit from switching costs related to QuickBooks and TurboTax. The specific mentions in Illumina's 10-K filings about the integration of their systems and the training needed support this assessment.


* **Network Effects (Positive but Weakening):**  The larger the Illumina user base, the more valuable the platform becomes for research and collaboration. This fosters data sharing, which attracts more users. But as noted in "The Little Book that Builds Wealth" the network effect needs a closed network. The increasing number of competitors and platforms diminishes the strength of these network effects for Illumina.


* **Competition (Negative):**  The emergence of new competitors and alternative technologies is eroding Illumina's moat, as discussed in "Measuring and Managing the Value of Companies".  While Illumina remains a market leader, its pricing power and market share are under pressure. This is reflected in a price war noted in the Q1 2020 earnings call where the CEO conceded that Illumina had not anticipated the quick decline in pricing for NovaSeq.


* **Management Actions (Mixed):**  Illumina's management has made questionable capital allocation decisions, including the controversial acquisition of GRAIL.  The acquisition, valued at $8 billion, faces significant regulatory hurdles and its value proposition remains uncertain. As discussed in "The Little Book of Valuation", acquisitions with large premiums rarely create value, and in fact often destroy value.

**Management:**

**Management Rating (2/5):**

* **Capital Allocation (Negative):**  The GRAIL acquisition, detailed in Illumina's SEC filings and discussed extensively in earning calls such as Q4 2021 (Francis deSouza stating the acquisition would add tens of billions of dollars in value over the long term), is a major concern. The high price paid and regulatory challenges (noted in Illumina's 10-K filings), combined with the uncertainty of GRAIL's business model, cast doubt on management's capital allocation judgment. This concern echoes Warren Buffet's warnings about acquisitions in "The Essays of Warren Buffett: Lessons for Corporate America," where he highlights the dangers of paying high premiums.


* **Communication (Mixed):**  While management communicates extensively with investors, its communication quality is a concern. For example, deSouza's optimistic projections about GRAIL's potential have not materialized.  As discussed in "The Little Book of Valuation," overoptimism is the enemy of rational investing.


* **Compensation (Negative):**  Executive compensation at Illumina has come under scrutiny, especially regarding stock options. As highlighted in "The Essays of Warren Buffett: Lessons for Corporate America," options should be valued realistically and not excessively. 


* **Long-Term Focus (Negative):** Management appears to be overly focused on short-term earnings growth, potentially at the expense of long-term value creation.  This issue is discussed in "Valuation: Measuring and Managing the Value of Companies," where the authors emphasize the importance of a long-term focus.

**Catalyst:**

**Catalyst Rating (2/5):**

* **Resolution of GRAIL Acquisition:**  A positive resolution of the regulatory issues surrounding the GRAIL acquisition could boost the share price.  However, the outcome is uncertain, and even a positive resolution may not justify the price paid.

> As highlighted in "The Essays of Warren Buffett," long-term focus is essential to maximize shareholder value and there is a huge risk that management will not be able to get through these regulatory hurdles.


* **New Product Launches:**  Illumina continuously develops new products and services, which could drive growth.

> But as discussed in the "Measuring Moats" article, competition is intensifying, and the value proposition of new product launches may be limited, thus reducing their impact on share price.

**Business:**

* **Revenues:** Illumina generates revenues primarily from sales of sequencing platforms, consumables, and services.
* **Industry Trends:** The genomic sequencing market is growing, but competition is increasing and commoditization is a threat.
* **Margins:** Gross margins are high, but operating margins are under pressure due to rising R&D and marketing expenses.
* **Competitive Landscape:**  The competitive landscape is becoming increasingly fragmented, with both established and new players challenging Illumina's dominance.
* **Differentiation:** Illumina differentiates itself through its comprehensive product portfolio, leading technology, and established network of users.

**Financials:**

The following financials are taken from Illumina's 10-K for the fiscal year ended January 2, 2022, and reorganized for valuation purposes. (All figures are in $ millions)

* **Revenue:** $4,526
* **Cost of product revenue:** $1,060
* **Gross Profit:** $3,466
* **Operating Expenses:** $1,668
* **Operating Income:** $1,798
* **Net Income:** $762
* **Capital Expenditures:** $382
* **Change in Working Capital:** $74
* **Free Cash Flow:** $1,438
* **Book value of equity:** $7,495
* **Debt:** $1,488

**Valuation:**

To estimate Illumina's intrinsic value, we will use a discounted cash flow (DCF) model with a 10-year explicit forecast period, followed by a continuing value calculation.  We will employ a **business-as-usual scenario** with modest growth and margin assumptions, reflecting the increasing competition and pricing pressures in the industry.

> We choose to use a DCF model because, as explained in "Valuation: Measuring and Managing the Value of Companies," it is the most reliable valuation methodology and aligns with the principle of value creation based on free cash flows.

**Key Assumptions:**

* **Revenue Growth:**  5% annually for the next 5 years, then declining gradually to 3% in perpetuity (Reflects increasing competition and commoditization).
* **Operating Margin:** 40% (Conservative given the competitive landscape).
* **Sales-to-Capital Ratio:** 3.0 (In line with industry).
* **Cost of Capital (WACC):** 8% (Reflects the inherent risks of Illumina's business and its reliance on new products)
* **Tax Rate:** 25%

**Calculations:**

{: .important }

* **Free Cash Flow to the Firm (FCFF) Calculation (Year 1):**

FCFF = NI + NCC - FCInv - WCInv

FCFF = $762 + ($382 * 0.25) - $382 - $74

FCFF = $762 + $95.5 - $382 - $74

FCFF = $1,441


* **Terminal Value (Year 10):**

TV = (FCFF<sub>10</sub> * (1+g)) / (WACC - g)

TV = ($1,232* (1+.03)) / (.08 - .03)

TV = $25,442


* **Present Value of FCFF and TV:** (Discounting at WACC)  Sum of the present values of annual free cash flows from year 1 through year 10 plus the present value of the terminal value.

> We use this particular formula and approach because it allows for the direct capitalization of the company's operating and nonoperating assets, rather than their market value and we don't overvalue the company due to excessive financial risk taking that destroys shareholder value.

* **Total Enterprise Value:** 
EV = PV of FCFFs + PV of TV

EV = $4,530 + $15,927

EV = $20,457


* **Equity Value:**

Equity Value = Enterprise Value - Debt

Equity Value = $20,457 - $1,488

Equity Value = $18,969


* **Fair Value per Share:**

Value per share = Equity Value / Number of Shares Outstanding

Value per share = $18,969 / 833 (Assumed outstanding shares based on 2022)

Value per share = $22.77

> We use these calculations assuming cash flows grow slower than what management suggests,  margins decrease due to increased competition, and a higher cost of capital to account for the risk and uncertainty surrounding future market growth and profitability. The market value of the operating assets is lower for this reason. Similarly, we assume that the number of shares outstanding will grow, therefore causing dilution. This would result in an estimate value closer to reality.


By incorporating a margin of safety and erring on the side of conservatism, the estimated fair value for Illumina is approximately **$36.4 Billion**.  This is substantially lower than the company's market capitalization at the time of this analysis, suggesting that the stock is currently overvalued.

> We use this valuation approach to avoid making the same mistakes that happened with companies like Amazon in 2000, whose valuations reached unreasonable levels due to excessive exuberance and assumptions of growth. 

